Neuropsychopharmacology
- Beyond traditional pharmacology: evaluating phosphodiesterase inhibitors in autism spectrum disorder2 years ago
- AM6527, a neutral CB1 receptor antagonist, suppresses opioid taking and seeking, as well as cocaine seeking in rodents without aversive effects2 years ago
- The selective D3Receptor antagonist VK4-116 reverses loss of insight caused by self-administration of cocaine in rats2 years ago
- Author Correction: Sex differences in offspring risk and resilience following 11β-hydroxylase antagonism in a rodent model of maternal immune activation2 years ago
- The rostromedial tegmental nucleus gates fat overconsumption through ventral tegmental area output in male rats2 years ago
- Retraction Note: Association between neuromelanin-sensitive MRI signal and psychomotor slowing in late-life depression2 years ago
- Altered excitatory and inhibitory ionotropic receptor subunit expression in the cortical visuospatial working memory network in schizophrenia2 years ago
Journal of Psychopharmacology
- Effects of CYP2D6*4 polymorphism on the steady-state concentration of paroxetine in patients diagnosed with depressive episode and comorbid alcohol use disorder3 years ago
- Clozapine-specific proliferative response of peripheral blood-derived mononuclear cells in Japanese patients with clozapine-induced agranulocytosis3 years ago
- Examining the role of systemic chronic inflammation in diet and sleep relationship3 years ago
- Systematic review and meta-analysis of augmentation and combination treatments for early-stage treatment-resistant depression3 years ago
- Sodium oxybate for the maintenance of abstinence in alcohol-dependent patients: An international, multicenter, randomized, double-blind, placebo-controlled trial3 years ago
- The CannTeen Study: Cannabis use disorder, depression, anxiety, and psychotic-like symptoms in adolescent and adult cannabis users and age-matched controls3 years ago
- MDMA-assisted therapy for posttraumatic stress disorder: A pooled analysis of ethnoracial differences in efficacy and safety from two Phase 2 open-label lead-in trials and a Phase 3 randomized, blinded placebo-controlled trial3 years ago
European Neuropsychopharmacology
- Rates of psychotropic medicine prescribing in paediatric populations in Australian general practice from 2000-20163 years ago
- Effect of psychotropics on the risk of COVID-19 in Middle-Aged and Older Adults3 years ago
- Sexual orientation as an important factor in personalized medicine3 years ago
- Single dose S-ketamine rescues transcriptional dysregulation of Mtor and Nrp2 in the prefrontal cortex of FSL rats 1hour but not 14 days post dosing3 years ago
- Delay in pharmacological treatment of autistic children after recognition of the disorder3 years ago
- Ayahuasca’s therapeutic potential: What we know – and what not3 years ago
- Psychiatric vulnerability in animal models3 years ago